Opening book details…
Can I read Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated with Second-Line Therapies for Medicare Patients with Advanced Non-Small Cell Lung Cancer on EtoBox?
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated with Second-Line Therapies for Medicare Patients with Advanced Non-Small Cell Lung Cancer by Arunachalam, Ashwini; Li, Haojie; Bittoni, Marisa A.; Camacho, Ramon; Cao, Xiting; Zhong, Yichen; Lubiniecki, Gregory M.; Carbone, David P. is a Medicine article available to read on EtoBox.
What is Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated with Second-Line Therapies for Medicare Patients with Advanced Non-Small Cell Lung Cancer about?
## Introduction: Real-world data on current treatment practices for non-small-cell lung cancer (nsclc) are needed to understand the place in therapy and potential economic impact of newer therapies. ## Patients and methods: This retrospective cohort study identified patients ≥ 65 years old in the surveillance, epidemiology, and end results (seer)-medicare linked database with first-time diagnosis of stage iiib/iv nsclc from 2007-2011 who received second-line therapy after first-line platinum-based chemotherapy from 2007 through mid-2013. second-line regimens, health care resource use, adverse events (aes), and associated costs were analyzed descriptively. overall survival was determined by kaplan-meier test. costs were adjusted to 2013 us dollars. ## Results: We identified 4033 patients with advanced nsclc who received second-line therapy (47% of those who received first-line platinum-based chemotherapy). mean (sd) age was 73 (5) years, 2246 (56%) were male; 1134 (28%) and 2899 (72%) had squamous and nonsquamous nsclc, respectively. the 4 most common second-line regimens were pemetrexed (22%), docetaxel (12%), carboplatin/paclitaxel (11%), and gemcitabine (7%). median overall survi
Who reads Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated with Second-Line Therapies for Medicare Patients with Advanced Non-Small Cell Lung Cancer?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Arunachalam, Ashwini; Li, Haojie; Bittoni, Marisa A.; Camacho, Ramon; Cao, Xiting; Zhong, Yichen; Lubiniecki, Gregory M.; Carbone, David P.
- Publisher
- CIG Media Group, LP.; Elsevier ; Elsevier Inc.; Elsevier BV (ISSN 1525-7304)
- Published
- 2018
- Language
- EN
- Field
- Medicine (Health Sciences)